Arcutis Biotherapeutics, Inc. Common Stock

ARQTNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
26.04 USD
↘ 0.39 (1.48%)🟢LIVE (AS OF 10:27 AM EDT)
🟢Market: OPEN

Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is currently trading at $26.04. Our models show a "Neutral" technical signal alongside a "Buy" fundamental rating. Key drivers include a robust Altman Z-Score and a bullish Golden Cross on the moving averages. Furthermore, ARQT is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Aug 6, 2026.

Open?$26.65
High?$27.67
Low?$25.85
Prev. Close?$26.43
Volume?288.7K
Avg. Volume?1.6M
VWAP?$26.27
Rel. Volume?0.19x
Bid / Ask
Bid?$26.06 × 100
Ask?$29.99 × 100
Spread?$3.93
Midpoint?$28.03
Valuation & Ratios
Market Cap?3.3B
Shares Out?125.1M
Float?113.0M
Float %?90.3%
P/E Ratio?116.49
P/B Ratio?15.06
EPS?$0.23
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Themes
Biotech - Drug Development›Immunology & Autoimmune
Employees
354
Market Cap
3.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.arcutis.com
Listed
2020-01-31
Address
3027 TOWNSGATE ROAD
WESTLAKE VILLAGE, CA 91361
Phone: 805-418-5006
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
100
Momentum?
85
Short Sent.?
34
Piotroski F-Score?5/9Mixed
Altman Z-Score?6.12Safe
Confidence?61%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.01%High
Short Interest?13.6M
Days to Cover?9.3
Free Float113.0M
Avg Daily Volume1.5M
Settlement Date2026-07-15
Financial Health
Current Ratio?2.92Strong
Quick Ratio?2.67Strong
Cash Ratio?0.21Low
Debt/Equity?0.49Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
33/100
P/E?
Peers
100
S&P
3
116.5PRICEY▾
P/B?
Peers
100
S&P
12
15.06HIGH▾
P/S?
Peers
100
S&P
16
7.16HIGH▾
P/FCF?
Peers
100
S&P
3
84.9PRICEY▾
EV/EBITDA?
Peers
100
S&P
3
96.0HIGH▾
EV/Sales?
Peers
100
S&P
19
7.32HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
47
12.9%STRONG▾
ROA?
Peers
50
S&P
52
5.8%FAIR▾
Cash Flow & Enterprise
FCF?$39.2M
Enterprise Value?$3.4B
Fundamentals ratios updated end of day
MarketsMoversWatchlist